STOCK TITAN

Charles River (NYSE: CRL) director receives stock grants instead of fees

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Charles River Laboratories International director George Llado Sr. reported receiving equity-based compensation in the form of common stock awards. On May 8, 2026, he acquired 450 shares and a separate award of 1,438 shares, both at an indicated price of $177.62 per share.

Footnotes explain these are unvested restricted stock units that vest upon the earlier of May 8, 2027 or the business day prior to the company’s next annual meeting of shareholders. One grant was made in lieu of director service fees for the term commencing May 5, 2026.

Positive

  • None.

Negative

  • None.
Insider Llado George Sr.
Role null
Type Security Shares Price Value
Grant/Award Common Stock 1,438 $177.62 $255K
Grant/Award Common Stock 450 $177.62 $80K
Holdings After Transaction: Common Stock — 6,252 shares (Direct, null)
Footnotes (1)
  1. The unvested restricted stock units vest upon the earlier of 5/8/2027 or the business day prior to the Company's next annual meeting of shareholders. The grant was made in lieu of director service fees for the term commencing May 5, 2026. The restricted stock units vest upon the earlier of 5/8/2027, or the business day prior to the Company's next annual meeting of shareholders.
Grant 1 shares 450 shares Common Stock grant on May 8, 2026
Grant 1 price $177.62 per share Indicated price for 450-share award
Grant 1 holdings after 6,702 shares Total common shares following 450-share grant
Grant 2 shares 1,438 shares Second Common Stock grant on May 8, 2026
Grant 2 price $177.62 per share Indicated price for 1,438-share award
Grant 2 holdings after 6,252 shares Total common shares following 1,438-share grant
Vesting date May 8, 2027 RSUs vest by this date or before next annual meeting
restricted stock units financial
"The unvested restricted stock units vest upon the earlier of 5/8/2027..."
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
director service fees financial
"The grant was made in lieu of director service fees for the term..."
annual meeting of shareholders financial
"or the business day prior to the Company's next annual meeting of shareholders."
A yearly gathering where a company’s owners (shareholders) vote on key items like electing the board, approving executive pay, and ratifying auditors, and receive updates on performance and strategy. Think of it as an annual town hall for owners: it matters to investors because outcomes and disclosures can affect leadership, corporate direction, dividend and governance policies, and therefore the company’s risk and potential return.
grant, award, or other acquisition financial
"transaction_code_description: Grant, award, or other acquisition"
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Llado George Sr.

(Last)(First)(Middle)
C/O CHARLES RIVER LABORATORIES
251 BALLARDVALE STREET

(Street)
WILMINGTON MASSACHUSETTS 01887

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. [ CRL ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/08/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock05/08/2026A1,438(1)A$177.626,252D
Common Stock05/08/2026A450(2)A$177.626,702D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. The unvested restricted stock units vest upon the earlier of 5/8/2027 or the business day prior to the Company's next annual meeting of shareholders.
2. The grant was made in lieu of director service fees for the term commencing May 5, 2026. The restricted stock units vest upon the earlier of 5/8/2027, or the business day prior to the Company's next annual meeting of shareholders.
/s/ George Llado Sr.05/11/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did CRL director George Llado Sr. report?

George Llado Sr., a director of Charles River Laboratories (CRL), reported receiving two equity awards: 450 shares and 1,438 shares of common stock on May 8, 2026. These awards are compensation grants, not open-market purchases or sales.

Were George Llado Sr.’s CRL stock awards open-market purchases?

No, the CRL transactions are coded as grants or awards, not open-market purchases. The Form 4 describes them as acquisitions under code “A,” indicating compensation-related grants rather than discretionary buying of shares in the market.

How many CRL shares did George Llado Sr. hold after these transactions?

After one grant of 450 shares, his reported direct holdings were 6,702 CRL common shares. After the separate grant of 1,438 shares, the filing shows direct holdings of 6,252 shares for that line, reflecting reporting for each award separately.

When do George Llado Sr.’s CRL restricted stock units vest?

The unvested restricted stock units vest on the earlier of May 8, 2027, or the business day before Charles River Laboratories’ next annual meeting of shareholders. This schedule applies to both the existing unvested units and the new grant made in lieu of director fees.

Why did CRL grant restricted stock units to director George Llado Sr.?

One of the CRL grants was issued in lieu of director service fees for the term beginning May 5, 2026. Instead of receiving cash fees, the director received restricted stock units that will vest based on the specified future vesting schedule tied to the annual meeting.